Michigan State University
Efficacy and mechanistic studies of a novel small molecule therapeutic agent "XB05" in acute myeloid leukemia (AML
Abstract
dc:descriptionAcute myeloid leukemia (AML) is the most common acute leukemia in adults characterized by a clonal proliferation of myeloid precursors with a reduced capacity to differentiate into more mature cellular elements resulting in pancytopenia. Current treatment options include induction chemotherapy followed by consolidation and hematopoietic stem cell transplantation (HSCT). DNA hypomethylating agents such as decytabine have been used to treat AML, especially in older patients. The drug has shown significant clinical benefit in a recent Phase III trial in older patients demonstrating the proof of concept of inhibiting DNA methylation as a therapeutic strategy in AML. We have discovered a novel synthetic small molecule, named XB05 that has potent activity against myeloid leukemia cell lines. Its precise molecular mechanism is not yet fully understood; however, we believe that it induces leukemia cell death through multiple mechanisms, including reactivation of tumor suppressor genes via inhibition of DNA methylation. In this study, mechanistic studies were performed with this novel agent in previously established leukemia cell lines.
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Grewal, Jaspreet Singh
- Contributors dc:contributor
-
- Thorne, David
- Malik, Tariq
- Gerlach, John
Subjects
dc:subject × 1Rights
dc:rights- Statement dc:rights
-
- In Copyright
- Language dc:language
- English
Identifiers
dc:identifier.*- Identifier
-
etd:2877
isbn:9781321425949
isbn:1321425945
oclc:973326453
umi:1571490
local:Grewal_grad.msu_0128N_13406 - OAI record oai:identifier
- https://d.lib.msu.edu/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Ad.lib.msu.edu%3Aetd_2877